<DOC>
	<DOCNO>NCT02185794</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral activity GS-9857 alone sofosbuvir ( SOF ) /GS-5816 fix dose combination ( FDC ) adults genotype 1 , 2 , 3 , 4 hepatitis C virus ( HCV ) infection . All participant monitor 48 week last dose monitor persistence viral mutation .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Antiviral Activity GS-9857 Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Chronic genotype 14 HCV infection For Cohorts 19 , HCV RNA â‰¥ 100,000 IU/mL screening ( HCV RNA restriction Cohort 10 ) Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Presence cirrhosis Prior exposure approve experimental HCV Protease Inhibitors Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HCV genotype 1 ( GT-1 )</keyword>
	<keyword>HCV genotype 2 ( GT-2 )</keyword>
	<keyword>HCV genotype 3 ( GT-3 )</keyword>
	<keyword>HCV genotype 4 ( GT-4 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Open Label</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>